fingolimod hydrochloride has been researched along with Graft vs Host Disease in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Ghobrial, RM; Kloc, M; Subuddhi, A; Ubelaker, HV; Uosef, A; Zou, D | 1 |
| Baek, JA; Cho, KH; Cho, ML; Choi, JW; Choi, JY; Jhun, J; Kim, SY; Park, MJ; Park, SH; Ryu, J | 1 |
| Chen, S; Chen, W; Ghobrial, RM; Kloc, M; Uosef, A | 1 |
| Chauvet, P; Coiteux, V; Gauthier, J; Magro, L; Varlet, P; Vermersch, P; Yakoub-Agha, I | 1 |
| Fujimoto, M; Hamaguchi, Y; Hasegawa, M; Huu, DL; Jin, G; Matsushita, T; Takehara, K | 1 |
| Chen, Y; Cheng, Q; Gong, H; Hu, B; Lei, L; Lin, D; Liu, H; Ma, S; Mei, Y; Wu, Y; Yu, X; Zhao, L; Zhao, Y | 1 |
| Applequist, SE; Fauriat, C; Heuts, F; Höglund, P; Juarez, JG; Kärre, K; Lakshmikanth, T; Ljunggren, HG; Muvva, SS; Persson, AK; Svensson, M; Wallin, RP | 1 |
| Huang, MX; Ito, T; Song, JH; Wei, JM | 1 |
| Eshhar, Z; Marcus, A; Waks, T | 1 |
| Bade, ND; Blazar, BR; Kelly, RM; Smith, MJ; Stefanski, HE; Taylor, PA | 1 |
| Asavaroengchai, W; Bronson, R; Kim, YM; Sachs, T; Sykes, M | 1 |
| Hogan, WJ; Kuhr, CS; Lee, RS; Little, MT; Sale, GE; Storb, R; Zellmer, E | 1 |
| Chiba, K | 1 |
| Ito, T; Matsuda, C; Matsuda, H; Miao, G; Nishida, T; Nozawa, M; Sawa, Y; Song, J; Tanemura, M | 1 |
| Aoyama, K; Asakura, S; Hashimoto, D; Koyama, M; Matsuoka, K; Sakoda, Y; Tanimoto, M; Teshima, T | 1 |
| Ito, T; Matsuda, C; Nishida, T; Nozawa, M; Sawa, Y; Song, J; Tanemura, M | 1 |
| Blazar, BR; Brinkmann, V; Ehrhardt, MJ; Lees, CJ; Panoskaltsis-Mortari, A; Serody, JS; Taylor, PA; Tolar, J; Weigel, BJ | 1 |
| Amemiya, H; Chiba, K; Hoshino, Y; Kakefuda, T; Kataoka, H; Kawaguchi, T; Rahman, F; Suzuki, S | 1 |
1 review(s) available for fingolimod hydrochloride and Graft vs Host Disease
| Article | Year |
|---|---|
FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Topics: Animals; Autoimmune Diseases; Calcineurin Inhibitors; Clinical Trials as Topic; Disease Models, Animal; Drug Synergism; Fingolimod Hydrochloride; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymph Nodes; Lymphocytes; Peyer's Patches; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Spleen; T-Lymphocytes; Thymus Gland | 2005 |
18 other study(ies) available for fingolimod hydrochloride and Graft vs Host Disease
| Article | Year |
|---|---|
Comparative transcriptome profile of mouse macrophages treated with the RhoA/Rock pathway inhibitors Y27632, Fingolimod (Gilenya), and Rezurock (Belumosudil, SLx-2119).
Topics: Actins; Animals; Fibrosis; Fingolimod Hydrochloride; Graft vs Host Disease; Humans; Macrophages; Mice; rho-Associated Kinases; rhoA GTP-Binding Protein; Transcriptome | 2023 |
FTY720 ameliorates GvHD by blocking T lymphocyte migration to target organs and by skin fibrosis inhibition.
Topics: Animals; Fibrosis; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Propylene Glycols | 2020 |
Fingolimod (FTY720) prevents chronic rejection of rodent cardiac allografts through inhibition of the RhoA pathway.
Topics: Allografts; Animals; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Mice; Multiple Sclerosis; Propylene Glycols; Rats; Rodentia; Sphingosine | 2021 |
Successful treatment with fingolimod of graft-versus-host disease of the central nervous system.
Topics: Aged; Allografts; Central Nervous System Diseases; Fingolimod Hydrochloride; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Receptors, Lysosphingolipid; Treatment Outcome | 2018 |
FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
Topics: Animals; Bone Marrow Transplantation; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Flow Cytometry; Graft vs Host Disease; Immunohistochemistry; Immunosuppressive Agents; Male; Mice; Propylene Glycols; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Scleroderma, Localized; Skin; Sphingosine; Spleen | 2013 |
The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment.
Topics: Animals; Bone Marrow Transplantation; Cell Movement; Chemokine CCL2; Chemokine CCL7; Disease Models, Animal; Fingolimod Hydrochloride; Gene Expression Regulation; Graft vs Host Disease; Human Umbilical Vein Endothelial Cells; Humans; Immunosuppressive Agents; Indans; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Monocytes; Oxadiazoles; Receptors, Lysosphingolipid; Severity of Illness Index; Signal Transduction; T-Lymphocytes; Whole-Body Irradiation | 2015 |
In vivo engineering of mobilized stem cell grafts with the immunomodulatory drug FTY720 for allogeneic transplantation.
Topics: Animals; Fingolimod Hydrochloride; Genetic Engineering; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Killer Cells, Natural; Lymphocyte Depletion; Mice; Mice, Knockout; T-Lymphocytes; Transplantation, Homologous | 2016 |
[FTY720-induced lymphocyte apoptosis inhibits acute graft versus host disease in rat small bowel transplantation].
Topics: Animals; Apoptosis; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Intestine, Small; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred WF; Sphingosine; Transplantation, Heterotopic | 2010 |
Redirected tumor-specific allogeneic T cells for universal treatment of cancer.
Topics: Animals; Antigens, Neoplasm; Cell Separation; Fingolimod Hydrochloride; Flow Cytometry; Graft vs Host Disease; Immunosuppressive Agents; Immunotherapy, Adoptive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Propylene Glycols; Sphingosine; T-Lymphocytes; Transplantation, Homologous | 2011 |
FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal.
Topics: Animals; Antibodies, Monoclonal; B-Lymphocytes; Bone Marrow Transplantation; CD40 Ligand; Cell Movement; Drug Synergism; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Graft vs Host Disease; Immunosuppressive Agents; Killer Cells, Natural; Mice; Propylene Glycols; Sphingosine; T-Lymphocytes; Thymocytes; Thymus Gland; Transplantation Chimera; Transplantation, Homologous; Whole-Body Irradiation | 2012 |
Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.
Topics: Animals; Bone Marrow Transplantation; Cell Movement; Female; Fingolimod Hydrochloride; Graft vs Host Disease; Graft vs Tumor Effect; Immunosuppressive Agents; Lymphocyte Activation; Lymphocytes; Male; Mice; Mice, Inbred Strains; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic | 2003 |
FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model.
Topics: Acute Disease; Animals; Dogs; Fingolimod Hydrochloride; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Immunosuppressive Agents; Lymphocyte Count; Propylene Glycols; Recurrence; Severity of Illness Index; Sphingosine | 2003 |
Inhibition of donor-derived T cells trafficking into target organs by FTY720 during acute graft-versus-host disease in small bowel transplantation.
Topics: Acute Disease; Animals; Body Weight; Cytokines; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Intestine, Small; Liver; Lymphocyte Count; Male; Propylene Glycols; Rats; Rats, Inbred WF; Skin; Sphingosine; T-Lymphocyte Subsets; Transplantation Chimera | 2006 |
FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease.
Topics: Adjuvants, Immunologic; Administration, Oral; Adoptive Transfer; Animals; Apoptosis; Bone Marrow Transplantation; Cells, Cultured; Female; Fingolimod Hydrochloride; Graft vs Host Disease; Lymphocyte Activation; Lymphocyte Depletion; Lymphopenia; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; T-Lymphocytes | 2007 |
Regulation of donor T cells in the tolerant rats to graft-versus-host disease by FTY720 following small bowel transplantation.
Topics: Animals; Cytokines; Fingolimod Hydrochloride; Graft vs Host Disease; Immune Tolerance; Immunosuppressive Agents; Intestine, Small; Male; Propylene Glycols; Rats; Rats, Inbred ACI; Rats, Inbred WF; Sphingosine; T-Lymphocytes; Transplantation, Homologous; Transplantation, Isogeneic | 2006 |
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).
Topics: Animals; Cells, Cultured; Chemotaxis, Leukocyte; Combined Modality Therapy; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Immunotherapy, Adoptive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Sphingosine; Spleen; Survival Analysis; T-Lymphocytes, Regulatory; Transplantation Conditioning | 2007 |
An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation.
Topics: Animals; Cyclosporine; Dogs; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Graft vs Host Disease; Immunosuppressive Agents; Kidney Transplantation; Leukocyte Count; Propylene Glycols; Sphingosine | 1998 |
FTY 720.
Topics: Animals; Drugs, Investigational; Fingolimod Hydrochloride; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 1999 |